Stay updated on rAAVrh74.MCK.GALGT2 for DMD Clinical Trial
Sign up to get notified when there's something new on the rAAVrh74.MCK.GALGT2 for DMD Clinical Trial page.

Latest updates to the rAAVrh74.MCK.GALGT2 for DMD Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe webpage has been updated to reflect a new dose escalation trial for Duchenne Muscular Dystrophy (DMD) involving GALGT2, with significant changes in the trial's description and inclusion criteria. The principal investigator's name, Kevin Flanigan, MD, remains the same, but the version has been updated to v2.15.0.SummaryDifference25%
- Check34 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check70 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check91 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check98 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to rAAVrh74.MCK.GALGT2 for DMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the rAAVrh74.MCK.GALGT2 for DMD Clinical Trial page.